Therapies

Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic

1 month ago   |   By Xconomy

Sickle cell disease research is seeing a flurry of activity with several companies currently testing therapies for the genetic blood disorder and one company recently receiving FDA approval. Imara aims set itself apart from the pack and it is preparing to go public to support continued clinical development of its own sickle cell drug. In documents filed with securities regulators late last week, Imara set a preliminary $86 million target for its IPO. The Cambridge, MA-based company has applied for a Nasdaq listing under the stock symbol “IMRA.” Imara develops drugs that treat rare genetic...
Read more ...

 

Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test

Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test

1 month ago   |   By Xconomy

A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers. On Tuesday the company said one of those drugs, cabiralizumab, a Five Prime antibody that Bristol-Myers Squibb was testing in combination with its cancer immunotherapy nivolumab , failed to beat the standard of care in a Phase 2 trial in patients with pancreatic cancer. Cabiralizumab blocks a protein called colony-stimulating factor-1 in an effort to stymie the activation and survival of monocytes and macrophages. In preclinical tests in...
Read more ...

 


Search by Tags

   Therapies      Drug      Clinical      Applied      Drugs      Genetics      Research      NASDAQ      Protein      Boston      Boston blog main      Boston top stories      National blog main      National top stories      San Francisco blog main      San Francisco top stories      Beta-Thalassemia      Biotech      Bioverativ      BlueBird Bio      Clinical trials      CRISPR Therapeutics      Gene editing      Gene Therapy      Global Blood Therapeutics      H. Lundbeck A      S      Imara      Investing      LentiGlobin      Life Sciences      Lundbeckfonden Ventures      New Enterprise Associates      Rare disease drugs      Sangamo Therapeutics      Sickle cell disease      Venture Capital      Vertex Pharmaceuticals      Vertex Pharmaceuticls      Voxelotor      Therapeutics      Cancer      New York blog main      New York top stories      San Francisco      Antibodies      Bristol-myers Squibb      Cancer      Cancer Drug      Drug Development      Five Prime      Pancreatic Cancer  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the... Read more ...

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is... Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a... Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic... Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Community Health Watch Study to Enhance the COVID-19 Pandemic Response

We're facing times that many of us could never have imagined due to COVID-19. We want to improve how health care systems respond to pandemics. Through the “Pandemic Response... Read more ...